ScreenerHero

RLMD Relmada Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · relmada.com
3.250USD-0.91%Mkt Cap: 346.68M $P/E: —

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docet…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap346.68M USD
Enterprise Value132.15M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-57.39M USD
Revenue/Share—
Last Price3.250 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-8.00
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B1.69
EPS (TTM)-0.91
EPS (Forward)-0.41
52W Range
1.52527% of range8.000
52W High8.000 USD
52W Low1.525 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-66.33%
ROA-61.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.79M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-6.82%
Net Debt-217.73M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio29.52
Quick Ratio29.34
Book Value/Sh1.94 USD
Cash/Share2.04 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 30, 2019
Splits
Last Split1:4
Split DateSep 30, 2019
Analyst Consensus
Rating—
Target (Mean)10.75 USD
Upside (mean)+230.8%
Target Range9.000 USD – 12.00 USD
9.000+230.8% to mean12.00
# Analysts4
Ownership
Shares Out.106.67M
Float82.64M
Insiders3.23%
Institutions94.66%
Short Interest
Short Ratio12.4d
Short % Float14.40%
Short % Out.13.56%
Shares Short14.46M
Short (prev mo.)12.89M
Technical
SMA 504.494 (-27.7%)
SMA 2005.455 (-40.4%)
Beta0.51
S&P 52W Chg16.45%
Avg Vol (30d)1.21M
Avg Vol (10d)1.11M
Technical Indicators
RSI (14)24.6
MACD-0.3580
MACD Signal-0.3226
MACD Hist.-0.0355
BB Upper4.697 USD
BB Middle3.929 USD
BB Lower3.161 USD
BB Width39.08%
ATR (14)0.2320 USD
Vol Ratio (20d)1.11x